Post-herpetic autoimmune encephalitis with refractory neuropsychiatric symptoms: a case report
Abstract
Case Presentation: A 22-year-old woman was admitted with a 7-day history of headache, fever, and vomiting, progressing to seizure and altered mental status. On examination, nuchal rigidity was present, and cerebrospinal fluid (CSF) analysis was positive for herpes simplex virus type 2 (HSV-2). Intravenous acyclovir was initiated, with clinical improvement, and she was discharged without focal neurological deficits, except for sphincter dysfunction. One month later, she was readmitted with motor deficit, hypersalivation, speech impairment, and behavioral changes. Repeat CSF showed no evidence of infection. Brain magnetic resonance imaging demonstrated extensive bilateral, asymmetric T2/FLAIR hyperintensities in the white matter with limbic predominance, associated with mild mass effect, supporting postherpetic autoimmune encephalitis. High-dose intravenous methylprednisolone followed by plasma exchange resulted in radiological improvement and resolution of speech impairment; however, severe behavioral abnormalities persisted, including hyperorality, hypersexuality, and heteroaggression, reflecting a refractory course. Cyclophosphamide was subsequently administered without significant clinical improvement. Rituximab was then initiated, with a second dose after 15 days, leading to partial improvement of neuropsychiatric symptoms. Discussion: Herpes simplex encephalitis is the leading cause of sporadic viral encephalitis, with an incidence of 2–4 cases per million annually. It usually presents as an acute monophasic disease affecting the temporal and frontal lobes and may result in severe neurological damage. In some patients, neurological worsening occurs weeks after apparent recovery. Although a minority of cases are related to ongoing or reactivated viral infection, most are attributed to immune-mediated mechanisms triggered by HSV, frequently associated with antibodies against neuronal surface antigens, especially the N-methyl-D-aspartate receptor (NMDAR). This occurs in approximately 7–25% of cases after the initial episode and is characterized by seizures, movement disorders, and neuropsychiatric symptoms. Early immunotherapy with high-dose intravenous corticosteroids, with or without intravenous immunoglobulin or plasma exchange, is associated with better outcomes, although some patients require second-line agents. Final Comments: This report describes postherpetic autoimmune encephalitis, highlighting its diagnostic complexity and variability in treatment response. Persistent neuropsychiatric symptoms despite sequential immunomodulatory therapies underscore the heterogeneity of clinical outcomes and challenges in therapeutic decision-making. These findings reinforce gaps in the understanding of disease mechanisms, predictors of treatment response, and optimal therapeutic strategies. Early recognition and timely immunotherapy remain essential to reduce neurological morbidity and improve long-term functional outcomes.